A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1. Whether single and repeated daily doses of CG2001 are safe and well-tolerated 2. How much of the drug, if any, enters the bloodstream (pharmacokinetics)